Online Inquiry
Epithelial Tumors of the Prostate
Epithelial tumors of the prostate predominantly originate from the glandular epithelial cells of the prostate. Alfa Cytology is a world leader in the research of epithelial tumors of the prostate. With our extensive experience and advanced platform, we can provide the best solutions for you.
Introduction to Epithelial Tumors of the Prostate
Several epithelial cell types, including luminal, basal, and neuroendocrine cells, have been suggested as potential cells of origin for prostate cancer. The formation of epithelial tumors of the prostate involves a complex interplay of genetic, environmental, and hormonal factors. The following is the mechanism of epithelial tumors of the prostate.
Genetic Variations
Mutations in oncogenes, inactivation of oncogenes, and chromosomal abnormalities can lead to abnormal growth of prostate epithelial cells, thus promoting tumor development.
Hormonal influences
Prostate epithelial cells express androgen receptors and androgens play a crucial role in the normal function of the prostate. High levels of androgens stimulate cell growth and division, which can lead to proliferation of cells carrying genetic mutations.
Inflammation
Diseases such as prostatitis cause cellular damage, promote cell regeneration and proliferation. And these can induce an inflammatory microenvironment that is conducive to tumorigenesis, thus promoting tumorigenesis.
Classification of Epithelial Tumors of the Prostate
Epithelial tumors of the prostate can be divided into several categories, the most common of which is prostate adenocarcinoma, which accounts for approximately 95% of all prostate tumors. Other types of epithelial tumors, such as high-grade prostatic intraepithelial neoplasia, intraductal carcinoma of the prostate and prostatic acinar adenocarcinoma, account for a small percentage of prostate tumors.
| (Baso) Squamous Neoplasms of the Prostate | Glandular Neoplasms of the Prostate |
|
|
Therapy Development in Epithelial Tumors of the Prostate
| Name | Company | Country | Phase |
| Zoledronic acid | Novartis | Switzerland | Approved |
| Darolutamide | Bayer AG & Orion Corporation | Germany & Finland | Approved |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At Alfa Cytology, we are dedicated to advancing the understanding and treatment of prostate epithelial tumors through a comprehensive array of specialized services. Our company utilizes advanced methods and expertise to meet the specific requirements of prostate epithelial tumor research.
One-Stop Solutions for Epithelial Tumors of the Prostate
Offer complete development of small molecule inhibitors, from discovering lead compounds to enhancing their chemistry, screening, and adjusting them for better performance.
Link a toxic drug to a monoclonal antibody with a chemical linker for precise delivery and targeting tumor cells strongly.
Specific cells are modified, cultured and expanded, and finally the resulting cells are characterized to develop cellular drugs for the therapy of prostate cancer.
Tumor Model Development Services
Alfa Cytology offers a wide range of preclinical animal models to accelerate drug development, especially in prostate cancer research. We provide humanized, spontaneous, chemically induced, genetically engineered, syngeneic, CDX, PDX, and metastatic tumor models.
If you are looking for therapy development services for epithelial tumors of the prostate, our expert team can provide comprehensive support. By partnering with Alfa Cytology, you'll receive personalized consulting services and efficient project advancement. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
For research use only.